[ad_1]
AstraZeneca is still waiting for the go-ahead from the US drug regulator to restart the scientific trial of its potential Covid-19 vaccine within the United States, Chief Executive Pascal Soriot mentioned on Thursday.
“We are the sponsor of the US study. We then provided all this information to the FDA (US Federal Drug Administration) and we are waiting to hear their decision,” Soriot informed a digital World Economic Forum dialogue.
The US trial of AstraZeneca’s Covid-19 vaccine candidate, initially developed by the University of Oxford, stays on maintain whereas regulators examine an sickness in one of many members, even after a British research and different programmes outdoors of the United States have resumed.
US Health and Human Services Secretary Alex Azar mentioned on Wednesday the continued suspension confirmed the FDA took vaccine security critically.
A doc posted on-line by Oxford college final week acknowledged the sickness in a British participant that triggered the pause on Sept. 6 could not have been related to the vaccine.
[ad_2]
Source hyperlink